Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 239 clinical trials
Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02)

The purpose of this study is to evaluate efficacy of derazantinib monotherapy or derazantinib-atezolizumab in combination in patients with advanced urothelial cancer harboring fibroblast growth

atezolizumab
advanced urothelial carcinoma
cancer
FGFR1
renal function
  • 9 views
  • 13 Jun, 2022
  • 92 locations
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC (ATRACTIB)

This is a multicenter, open-label, single-arm, phase II clinical trial to evaluate to evaluate the efficacy and safety of first line atezolizumab in combination with paclitaxel and bevacizumab

  • 0 views
  • 19 Jun, 2022
  • 20 locations
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

. The study will evaluate participant- and healthcare professionals (HCP)-reported preference for atezolizumab subcutaneous (SC) compared with atezolizumab intravenous (IV).

adjuvant chemotherapy
lung carcinoma
atezolizumab
cancer chemotherapy
chemoradiotherapy
  • 1 views
  • 13 Jun, 2022
  • 31 locations
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte)

Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in

prophylactic cranial irradiation
lurbinectedin
atezolizumab
etoposide
carboplatin
  • 2 views
  • 30 Jun, 2022
  • 48 locations
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second

progressive disease
abiraterone
bone disease
apalutamide
serum testosterone
  • 0 views
  • 20 Apr, 2022
  • 223 locations
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (FIDES-03)

The purpose of this study is to evaluate the efficacy of derazantinib monotherapy or derazantinib in combination with paclitaxel, ramucirumab, or atezolizumab in patients with HER2-negative

  • 0 views
  • 07 Mar, 2022
  • 79 locations
ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (ABC-lung)

ETOP 15-19 ABC-lung is an international, multi-centre open-label, randomized phase II trial with two non-comparative parallel arms of atezolizumab plus bevacizumab with carboplatin-paclitaxel

Accepts healthy volunteers
  • 42 views
  • 24 Mar, 2022
  • 17 locations
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

This is a phase III, randomized, partially blinded, multicenter trial to evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared to placebo plus bevacizumab

  • 80 views
  • 14 Feb, 2022
  • 105 locations
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01)

The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally

EGFR
lung carcinoma
recurrent non-small cell lung cancer
atezolizumab
chemoradiotherapy
  • 0 views
  • 03 Mar, 2022
  • 33 locations
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)

combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with

pembrolizumab
etoposide
atezolizumab
cancer chemotherapy
carboplatin
  • 0 views
  • 30 Jun, 2022
  • 24 locations